Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Formulary 101: The Medicare Program Hosts A Cash Course In Therapeutic Alternatives

This article was originally published in RPM Report

Executive Summary

CMS and the Medicare private drug plans are using Medicare enrollment to teach seniors -- and their adult advisors -- about the cost savings from therapeutic interchange. Training patients to look for cost savings and to discuss costs with doctors is clearly a secondary objective of the Medicare enrollment process. The Medicare plan finder website and private plan sites carry frequent messages to alert beneficiaries cost savings. Pfizer responds with consumer-based pricing for Lipitor.

You may also be interested in...

Putting the Dough in the Donut Hole: Big Pharma Hits the Sweet Spot in the Reform Debate

It's not often than any industry group voluntarily agrees to give up $80 billion in future revenues, but that's what the Pharmaceutical Research & Manufacturers of America is pledging to do to in the context of the health care reform debate. There are a lot of details to work out, but this is a case where what is important is not what PhRMA is giving-but what it gets.

Dollars for Donuts: Inside the Key Elements of PhRMA's Health Reform Deal

The key part of PhRMA's deal with the Finance Committee is a double win for industry: assuring that closing the donut hole will be part of reform, and that PhRMA will get credit for a big part of the savings.

Protected Class Lobbying Begin

Bayer is CMS to add multiple sclerosis to the list of drug classes protected from formulary restrictions under the Medicare Part D prescription drug program. The first request to broaden the list of protected classes won't be the last.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts